Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities

- February 23rd, 2018

Helix BioPharma (TSX:HBP) a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has authorized a process to explore a partnership, alliance, joint development or licensing transaction of its L-DOS47 drug product candidate. Today’s announcement is part of Helix’s continuing efforts to effectively allocate … Continued

Helix BioPharma (TSX:HBP) a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has authorized a process to explore a partnership, alliance, joint development or licensing transaction of its L-DOS47 drug product candidate. Today’s announcement is part of Helix’s continuing efforts to effectively allocate resources and capital, and create value for its shareholders.

As quoted in the press release:

The intention of Helix is to enter a structured process that will include preparing the Company to have discussions with potential partners, engaging in dialogue with a targeted group of qualified partners and licensees, and entering negotiations on a prospective partnership, alliance or licensing transaction.

“We are very excited and pleased to be working with Deloitte Corporate Finance,” said Heman Chao, Helix’s Chief Executive Officer.

Click here to read the full press release.

The newest developments in genetics investing

 
Read our FREE outlook report on genetics investing

Leave a Reply